With the Agilent SureSelect Cancer CGP assay, a targeted, pan-cancer panel based on next-generation sequencing (NGS) technology, you’ll have access to the most clinically relevant and up-to-date biomarker content by detecting key classes of somatic alterations. Have confidence in high-performance results optimized with error-correcting molecular barcodes, convenient enzymatic fragmentation and minimum sample input. The workflow solution is configurable to meet the needs of your lab with options to incorporate sample QC, automation, and data analysis solutions.
Find out more on Agilent's website here
Newsletters
Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.
